ImmunoGen Announces Webcasts of Presentations at Upcoming Investor Conferences

WALTHAM, Mass.--()--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

  • Leerink Partners 6th Annual Global Healthcare Conference
    February 15, 2017 at 1:00pm ET
  • 2017 RBC Capital Markets Global Healthcare Conference
    February 23, 2017 at 9:30am ET
  • Cowen and Company 37th Annual Health Care Conference
    March 7, 2017 at 8:40am ET

The webcasts will be accessible live through the “Investors” section of the Company’s website, www.immunogen.com; a replay will be available at the same location for approximately a week.

About ImmunoGen
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate technology. ImmunoGen’s lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease. ImmunoGen’s ADC technology is used in Roche’s marketed product, Kadcyla®, in three other clinical-stage ImmunoGen product candidates, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com.

Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

Contacts

Investor Contact:
ImmunoGen, Inc.
Sarah Kiely, 781-895-0600
sarah.kiely@immunogen.com
or
Media Contacts:
ImmunoGen, Inc.
Amy Reilly, 781-895-0138
amy.reilly@immunogen.com
or
FTI Consulting Inc.
Robert Stanislaro, 212-850-5657
robert.stanislaro@fticonsulting.com

Recent Stories

RSS feed for ImmunoGen, Inc.

ImmunoGen, Inc.